Genetic Technologies (ASX:GTG) Ending Cash Position: A$1.02 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genetic Technologies Ending Cash Position?

Genetic Technologies ASX:GTG Ending Cash Position is A$1.02 Mil as of Jun. 2024.

Genetic Technologies's Ending Cash Position for the quarter that ended in Jun. 2024 was A$1.02 Mil.

Genetic Technologies's quarterly Ending Cash Position declined from Dec. 2023 (A$3.73 Mil) to Mar. 2024 (A$1.78 Mil) and declined from Mar. 2024 (A$1.78 Mil) to Jun. 2024 (A$1.02 Mil).

Genetic Technologies's annual Ending Cash Position declined from Jun. 2022 (A$11.73 Mil) to Jun. 2023 (A$7.85 Mil) and declined from Jun. 2023 (A$7.85 Mil) to Jun. 2024 (A$1.02 Mil).

Genetic Technologies Ending Cash Position Related Terms

Genetic Technologies Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies Ending Cash Position Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.21 20.90 11.73 7.85 1.02

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.90 3.73 1.78 1.02 1.62

Genetic Technologies Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Genetic Technologies's Ending Cash Position for the fiscal year that ended in Jun. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=7.852+-6.831
=1.02

Genetic Technologies's Ending Cash Position for the quarter that ended in Jun. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1.783+-0.762
=1.02

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$1.02 Mil mean?
Genetic Technologies (ASX:GTG) has a Ending Cash Position of A$1.02 Mil as of Jun. 2024. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Genetic Technologies and its competitors.
Is Genetic Technologies' Ending Cash Position too high?
Genetic Technologies' current Ending Cash Position is A$1.02 Mil.
How does Genetic Technologies' Ending Cash Position compare to LDDD and NOTV?
Genetic Technologies' Ending Cash Position of A$1.02 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Diagnostics & Research company?
A good Ending Cash Position depends on the Medical Diagnostics & Research industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Genetic Technologies and its competitors. Genetic Technologies's current Ending Cash Position is A$1.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (ASX:GTG) has a current Ending Cash Position of A$1.02 Mil. The current Ending Cash Position is A$1.02 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Genetic Technologies (ASX:GTG), the current Ending Cash Position is A$1.02 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.